利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.016 秒)

    COMPOSITIONS AND METHODS FOR USE IN ONCOLOGY
    7.
    发明公开
    COMPOSITIONS AND METHODS FOR USE IN ONCOLOGY 审中-公开
    ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG IN DER ONKOLOGIE

    公开(公告)号：EP3010552A1

    公开(公告)日：2016-04-27

    申请号：EP14731952.9

    申请日：2014-06-19

    申请人： Nanobiotix

    发明人： POUL, Laurence ,  LEVY, Laurent ,  BERJAUD, Céline ,  GERMAIN, Matthieu ,  POTTIER, Agnès

    IPC分类号： A61K49/04 ,  A61K9/08 ,  A61K9/51

    CPC分类号： A61K49/04 ,  A61K9/0024 ,  A61K9/06 ,  A61K49/0423 ,  A61K49/0457 ,  A61P35/00

    摘要： The present invention relates to compositions and methods for use in medical diagnostic and patient monitoring, typically in the context of therapy, in particular in the context of oncology to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticles aggregates, wherein i) the density of each nanoparticle and of each nanoparticle aggregate is of at least 7 g/cm3, the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s−1 of the gel comprising nanoparticles and/or nanoparticle aggregates, is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C. and 37° C.

    摘要翻译： 本发明涉及用于医学诊断和患者监测的组合物和方法，通常在治疗的上下文中，特别是在肿瘤学优化肿瘤床局部照射的背景下。 更具体地涉及包含纳米颗粒和/或纳米颗粒聚集体的生物相容性凝胶，其中i）每个纳米颗粒和每个纳米颗粒聚集体的密度为至少7g / cm 3，所述聚集体的纳米颗粒或纳米颗粒包含无机材料，其包含 至少一种原子序数Z为至少25，更优选至少为40的金属元素，所述纳米颗粒和所述纳米颗粒聚集体中的每一个被生物相容性涂层覆盖; ii）纳米颗粒和/或纳米颗粒聚集体浓度为至少约1％（w / w）; 和iii）当在20℃和37℃之间测量时，包含纳米颗粒和/或纳米颗粒聚集体的凝胶在2s -1处的表观粘度为约0.1Pa·s至约1000Pa·s。

    NANOPARTICLES DELIVERY SYSTEMS, PREPARATION AND USES THEREOF
    9.
    发明授权
    NANOPARTICLES DELIVERY SYSTEMS, PREPARATION AND USES THEREOF 有权

    公开(公告)号：EP2670394B1

    公开(公告)日：2018-11-21

    申请号：EP12702019.6

    申请日：2012-01-31

    申请人： Nanobiotix

    发明人： POTTIER, Agnès ,  LEVY, Laurent ,  MEYRE, Marie-Edith ,  GERMAIN, Matthieu

    IPC分类号： A61K9/127 ,  A61K9/51 ,  A61K49/00 ,  A61K49/18 ,  A61K41/00

    CPC分类号： A61K9/1271 ,  A61K9/5115 ,  A61K41/0028 ,  A61K49/0002 ,  A61K49/1812

    摘要： The invention pertains to thermosensitive liposomes encapsulating nanoparticles. In certain embodiments, the thermosensitive liposomes of the invention disrupt when heated at gel-to-liquid crystalline phase transition temperature (Tm) or above Tm, wherein the liposome comprises a thermosensitive lipidic membrane encapsulating nanoparticles. The nanoparticles used in the invention comprise an inorganic core the largest dimension of which is less than about 100 nm that is fully coated with an agent responsible for the presence of an electrostatic charge below −20 mV or above +20 mV at the surface of the nanoparticle, the electrostatic charge being determined by zeta potential measurements in an aqueous medium between pH 6 and 8, for a concentration of nanoparticles in suspension in the aqueous medium varying between 0.2 and 8 g/L. The invention also relates to pharmaceutical and diagnostic compositions comprising the thermosensitive liposomes as well as to their uses.

    PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF
    10.
    发明公开
    PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF 审中-公开
    药物组合物，制剂和用途

    公开(公告)号：EP3236934A1

    公开(公告)日：2017-11-01

    申请号：EP15798435.2

    申请日：2015-11-24

    申请人： Nanobiotix

    发明人： GERMAIN, Matthieu ,  MEYRE, Marie-Edith ,  POTTIER, Agnès ,  LEVY, Laurent

    IPC分类号： A61K9/00 ,  A61K41/00 ,  A61K9/127 ,  A61K47/50 ,  A61K51/12

    CPC分类号： A61K9/1271 ,  A61K9/0009 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/51 ,  A61K31/704 ,  A61K47/6911

    摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.

    摘要翻译： 本发明涉及药物组合物，其包含（i）至少一种生物相容性纳米颗粒和（ii）包含至少一种药物化合物的至少一种载体的组合，以待施用于需要这种药物化合物的受试者， 其中所述至少一种生物相容性纳米颗粒和包含所述药物化合物的所述至少一种载体的组合增强所述感兴趣的化合物效率。 生物相容性纳米粒子的最长尺寸典型地在约4和约500nm之间，并且其绝对表面电荷值至少为10mV（| 10mV |）。 另外载体没有任何表面空间稳定剂。 本发明还涉及用于在有需要的受试者中施用药物化合物的组合物，其中所述至少一种生物相容性纳米颗粒和包含所述至少一种药物化合物的所述至少一种载体分别施用 在需要所述药物化合物的受试者中，典型地在彼此之间超过5分钟至约72小时之间。